European Pharmaceutical Review

APRIL 3, 2023

The CHMP adopted a positive opinion for Epysqli (eculizumab), a biosimilar medicine for paroxysmal nocturnal haemoglobinuria. On 3 April 2023, the treatment was recommended by the CHMP for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+).

Vaccines 82

Vaccines Chemotherapy Generic Medicine Biosimilars 82

Express Pharma

JULY 3, 2023

For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. With our joint announcement on June 4, 2023, Waters and Sartorius entered a new phase of our collaboration, this time to support downstream bioprocessing as well.

Biosimilars 84

Biosimilars Drug Development Generic Medicine Diabetes 84

Quality Matters

JANUARY 23, 2023

USP looks forward to working with all stakeholders on implementation of these important initiatives in 2023. Improved supply chain visibility Longstanding medicines supply chain vulnerabilities – including those that could result in drug shortages – became even more evident during the COVID-19 pandemic.

Generic Medicine 52

Generic Medicine Pharmaceutical Manufacturing Biosimilars Communication 52

Quality Matters

APRIL 20, 2023

Launched in 2021 and composed of more than 250 million data points spanning 92% of generic medicines approved in the U.S., kristine.gates… Thu, 04/20/2023 - 08:51 Supply Chain

Biosimilars 52

Biosimilars Labelling Vaccines Generic Medicine 52

Pharmaceutical Technology

DECEMBER 15, 2022

On November 16, 2022, Medicines for Europe (MFE), the generics and biosimilars body, called for EU and national reforms to improve the security of medicine supplies, including tackling the impact of inflation on the security of essential medicine supplies with smart procurement guidelines for medicine.

Generic Medicine 98

Generic Medicine Drug Pricing Biosimilars Hospitals 98